Testing for erbB-2 by Immunohistochemistry in Breast Cancer
D. Craig Allred, MD, 1 and Paul E. Swanson, MD 2 The success of recent clinical trials using Herceptin (trastuzumab, a humanized anti-erbB-2 antibody) as therapy for patients with advanced breast cancer [1] [2] [3] has generated a great deal of renewed interest in laboratory testing for overexpression of the erbB-2 oncoprotein. An article by Jacobs et al 4 in this issue of the Journal describes an interesting study evaluating interlaboratory agreement in assessing overexpression of erbB-2 by permanent-section immunohistochemistry (IHC). In that study, adjacent tissue sections from 93 formalin-fixed paraffin-embedded breast cancer specimens were immunostained independently in 2 very experienced laboratories. They used the same polyclonal primary antibody but different automated immunostainers, detection systems, and methods of scoring the IHC signal. The rates of erbB-2 overexpression observed by the 2 laboratories were almost identical (23% and 24%), in line with the expected rate of 20% to 30% from many previous studies, and the agreement in interpreting cases as positive or negative for overexpression was 97%, which is remarkable.
Acknowledging that it can be problematic to obtain reproducible quantitative results when assessing any biomarker by IHC, including erbB-2, one can still conclude reasonably from this study 4 that experienced laboratories using the same primary antibody and otherwise sound but somewhat dissimilar methods can obtain consistent and reasonable results when measuring overexpression of erbB-2 by IHC. One cannot conclude from this study, as the authors acknowledge, 4 that testing for erbB-2 by IHC therefore needs no further validation or standardization before becoming part of routine clinical practice.
In fact, there are still large gaps in our understanding of the clinical usefulness of erbB-2 and how best to evaluate it. Because of these shortcomings, the College of American Pathologists and the American Society of Clinical Oncologists do not currently recommend using erbB-2 in the routine management of patients with breast cancer. [5] [6] [7] Despite this lack of endorsement, erbB-2 is being assessed in a large proportion of breast cancers in laboratories around the world, primarily by IHC using diverse and often unproven reagents and poorly standardized methods. While this practice is open to criticism, it probably is unrealistic to expect laboratories to stop performing tests for erbB-2 until comprehensive validation is achieved (even if it is the appropriate course), especially given the substantial pressure they are under to offer them. Considerable pressure comes from patients who understandably want the latest test they hear about in the news, even though the test still may be a research tool. Oncologists and pathologists have a role by ordering and performing tests without always understanding their limitations or how to interpret them. Industry contributes through overzealous advertising of untried reagents that are lucrative, which is compounded by laboratories whose business is based on using them. As compelling as these reasons may be, however, patients may be receiving inappropriate therapy owing to invalid erbB-2 test results, which will continue until better validation is achieved.
How might better validation be achieved? The issue of validating prognostic and predictive factors in breast cancer was debated hotly a decade ago when the scientific literature was inundated with conflicting studies on many factors. This debate culminated in published guidelines by oncologists and pathologists for measuring, interpreting, and using these factors. [5] [6] [7] [8] These recommendations basically agreed that, for a factor to be useful, it should have clinical and technical validation and influence therapeutic decision making. Clinical validation means that the factor has the ability to identify subsets of patients with significantly different risks of relapse, survival, or response to therapy. For factors that are used to select specific therapies, their usefulness should be verified in multiple large studies of randomized patients. Technical validation means that the assay used to measure the factor is sensitive, specific, reproducible, interpreted in a relatively uniform manner between laboratories, and (particularly important) calibrated to clinical outcome. Useful means that the results actually are used by clinicians to make treatment decisions. A brief overview of erbB-2 in clinical studies of breast cancer helps illuminate some of the strengths and weaknesses about its validation as a prognostic and predictive factor.
Other than the estrogen receptor, erbB-2 is perhaps the most thoroughly studied biomarker in breast cancer. Well over 50 studies have been published, involving more than 15,000 patients, assessing the relationship of erbB-2 with clinical outcome in one setting or another. [9] [10] [11] [12] The majority assessed overexpression by IHC and were based on nonrandomized patients, many of whom were treated with diverse types of systemic therapy, obscuring the prognostic and predictive implications of their results. A few studies, however, assessed untreated cohorts, and their results clearly showed that an abnormal erbB-2 phenotype is a prognostic factor for poor outcome, although a relatively weak one. [13] [14] [15] [16] [17] [18] The results of early studies suggested that erbB-2 was more prognostic in node-positive than in node-negative disease. 9, 10 This initially puzzling observation suggested that perhaps erbB-2 was a strong predictive factor for responsiveness (or lack thereof) to systemic therapy rather than a prognostic factor, since many of the early studies were based on patients treated during a time when systemic therapy after surgery was fairly restricted to patients with node-positive or advanced breast cancer. This hypothesis soon was tested in several studies, some of which were based on randomized controlled clinical trials ❚Table 1❚.
The first such studies looked at the relationship between overexpression of erbB-2 and therapy with cyclophosphamide, methotrexate, and fluorouracil (CMF), the prevailing type of cytotoxic systemic therapy used in many of the early studies. At least 5 notable studies have addressed this issue, and all showed a significant treatment benefit in erbB-2-negative but not in erbB-2-positive (ie, overexpressing) cases. 13, [19] [20] [21] [22] One was an adjuvant study with an untreated control arm and, although statistically underpowered owing to a small number of erbB-2-positive cases, it provided a fairly clear-cut indication that the relationship between erbB-2 and CMF was more predictive than prognostic. 13 Although the available data support the notion that erbB-2 is a marker of resistance to CMF, the issue is somewhat moot in the sense that newer drugs are replacing this type of therapy.
A great deal of attention recently has been given to the relationship between erbB-2 status and response to anthra- Cyclophosphamide, methotrexate, and fluorouracil Allred et al 13 Resistance IHC (21N) Gusterson et al 19 Resistance IHC (ICR12) Tetu and Brisson 20 Resistance IHC (21N) Stal et al 21 Resistance Flow cytometry (9G6) Vera et al 22 Resistance IHC (CB11) Anthracycline Muss et al 23 Sensitivity IHC (polyclonal) Thor et al 24 Sensitivity IHC (CB11) Gianni et al 25 Sensitivity FISH/amplification Paik et al 26 Sensitivity IHC (Tab250+pAb1) Ravdin et al 27 Sensitivity IHC (Tab250) Paik et al 28 Sensitivity IHC (Tab250+pAb1) Dieras et al 29 Sensitivity IHC (CB11) Dressler et al 30 Sensitivity FISH/amplification Untch et al 34 No relationship IHC (3B5) Vincent-Salomon et al 35 No relationship IHC (CB11) Harris et al 36 No relationship IHC (CB11) Tamoxifen Wright et al 37 Resistance IHC (21N) Borg et al 38 Resistance Southern blot/amplification Carlomagno et al 39 Resistance IHC (Tab250) Bianco et al 40 Resistance IHC (Tab250) Plunkett et al 41 Resistance IHC (na) Archer et al 42 No relationship IHC (pAb1) Elledge et al 43 No relationship IHC (Tab250) Paik et al 28 No relationship IHC (Tab250+pAb1) Muss et al 44 No cycline-containing regimens, such as cyclophosphamide, doxorubicin (Adriamycin), and fluorouracil, arguably the mainstay of cytotoxic systemic therapy in breast cancer today. Unlike the situation with CMF, where erbB-2 may be a marker of resistance, the majority of studies on this issue have shown significant associations between amplification or overexpression of erbB-2 and sensitivity to therapy. [23] [24] [25] [26] [27] [28] [29] [30] Interestingly, topoisomerase II-alpha, an important enzyme involved in DNA replication, often is coamplified and overexpressed with erbB-2 in breast cancers, which may explain partially how erbB-2 predicts for anthracycline sensitivity by acting as a surrogate for topoisomerase activity. [31] [32] [33] Although there have been a few small dissenting studies recently, [34] [35] [36] several of the studies showing a relationship between erbB-2 and responsiveness to anthracyclines were based on large controlled randomized trials, 23,24,26-28 strongly supporting the idea that erbB-2 is clinically useful in this setting. Several studies also have looked at erbB-2 and tamoxifen, the most popular systemic hormonal therapy in breast cancer. The results have been quite mixed; at least 5 studies have shown a significant relationship between amplified or overexpressed erbB-2 and resistance, 37-41 while 4 studies have revealed no relationship. 28, [42] [43] [44] Because of this controversy, there currently is no clear-cut role for erbB-2 as a predictive factor for success of tamoxifen therapy. However, these studies were diverse and difficult to compare, and many had limitations restricting their ability to enlighten us on this issue. At least 1 of the studies was well designed for assessing erbB-2 as a predictive factor in the sense that it was based on a relatively large number of patients randomized to adjuvant tamoxifen vs no treatment. 40 It showed a strong association between erbB-2 overexpression assessed by IHC and drug resistance, cautioning us to keep an open mind until additional studies clarify the clinical usefulness of erbB-2 in predicting response to tamoxifen. The outcome of such studies may well affect care in a large proportion of breast cancer patients.
The relationship between erbB-2 and Herceptin therapy has received the most attention recently, motivated primarily by the results of phase 2 and 3 clinical trials [1] [2] [3] showing a modest but significant improvement in patients with advanced breast cancer, which is fortunately a minority of patients. The benefit was restricted primarily to patients with tumors expressing very high levels of erbB-2, which is not too surprising given that Herceptin targets the oncoprotein. Hopefully, this success will hold up in future studies, especially those assessing the efficacy of Herceptin in an adjuvant setting (eg, the National Surgical Adjuvant Breast and Bowel Project [NSABP] B31), which potentially would benefit far more patients than just those with advanced disease.
Based on these studies and more, there is a growing consensus that erbB-2 is approaching or has even achieved clinical validation as a predictive factor for responsiveness to anthracyclines and Herceptin. There is far less accord on the best way to measure erbB-2 status in the laboratory. A glance at Table 1 illustrates the diverse technology that has been used in studies assessing the clinical usefulness of erbB-2 so far. None of these assays has been widely accepted as the standard for evaluating erbB-2 in the laboratory, although many of them are excellent methods and probably could have filled this role. Instead, most laboratories are using their own homegrown assays or, in many instances, the recently marketed HercepTest (Dako, Carpinteria, CA).
HercepTest is popular for several reasons, including name recognition due to similarity with the Herceptin drug, its recent approval by the US Food and Drug Administration (FDA), aggressive marketing by the manufacturer, and its "kit" format that is relatively easy to use and that promotes reproducibility because it contains comprehensive standardized reagents. Like all assays, however, it has shortcomings. For example, despite the similarity of names, HercepTest was not the same assay used in the Herceptin clinical trials. Patients were enrolled in these trials based on having tumors showing high levels of erbB-2 in IHC assays using monoclonal antibody 4D5 or CB11, while HercepTest uses a proprietary polyclonal antibody (Dako reference no. A0485). FDA approval of the HercepTest was based largely on a study showing 79% overall concordance of staining results between HercepTest and the IHC assays used in the Herceptin clinical trials in a series of more than 500 breast cancers unrelated to the Herceptin clinical trials, and it was not correlated with clinical outcome at all. In fact, HercepTest has not been used in any study published to date that shows the usefulness of erbB-2 as a predictive factor in any clinical setting. HercepTest is interpreted by assigning a numeric score ranging from 0 to 3 reflecting the intensity and pattern of the IHC signal present in 10% or more of tumor cells. This latter cutoff, intended to simplify the interpretation of a "positive" result, is entirely arbitrary and oversimplifies the limited but still significant heterogeneity of erbB-2 staining. Indeed, use of such an arbitrary scale may obscure the clinical importance of heterogeneity in erbB-2 overexpressing breast cancers. Nevertheless, HercepTest probably is a good test in terms of specificity, as suggested by the high (97%) level of interlaboratory agreement in assessing erbB-2 observed by Jacobs et al 4 (and highlighted by this editorial), which was based on IHC assays using the same primary antibody but different detection systems, as HercepTest. There may be a problem with sensitivity, however, as suggested in a recent study finding unreasonably high rates (up to 60%) of erbB-2 overexpression in a series of more than 1,000 breast cancers using HercepTest. 45 HercepTest soon will be compared with other IHC assays in studies assessing erbB-2 in various clinical settings, including the use of adjuvant Herceptin as planned in the upcoming © American Society of Clinical Pathologists NSABP B31 clinical trial. How well it stacks up against these other more established and less expensive assays hopefully will determine its ultimate usefulness in the laboratory.
Importantly, HercepTest emphasizes a widespread problem in laboratory testing for prognostic and predictive factors by IHC. Historically, IHC has been used primarily to determine the mere presence or absence or staining pattern of a particular protein to help identify cell or tissue type, without much need for quantifiable results. Prognostic and predictive factors, however, often are relatively continuous biologic variables that need to be quantified in a relatively precise manner, which is difficult for IHC even under the best of circumstances. Of particular importance, the quantified results need to be correlated with clinical outcome to determine the optimum value that may initiate a specific treatment decision. Unfortunately, many laboratories have not responded to these changing demands and are performing and interpreting IHC assays for prognostic and predictive factors in a highly varied and arbitrary manner. That HercepTest is packaged with an arbitrary (and, yes, FDA-approved) grading scale only compounds this problem. Patients will benefit when all laboratories performing these tests adopt reasonable technical standards based on clinical science.
Given the currently limited technical standardization and clinical validation of IHC testing for erbB-2 in breast cancer, what can laboratories that are already performing such tests do today? In the short term, until better standardization and validation are achieved, it makes sense to report staining results in a very explicit manner, annotated by footnotes or comments indicating the assay being used (especially naming the primary antibody) and citing references supporting its use. Reporting specific results, such as the percentage or proportion of positive cells and their intensity, avoids the use of general interpretations, such as positive or negative, that can be misleading, since these definitions may vary with the clinical setting for a given marker and since they have not been clearly defined for each assay or clinical setting. For example, studies so far suggest that responsiveness to anthracyclines may be associated with much lower levels of erbB-2 than responsiveness to Herceptin. Obviously, general interpretations of results as positive or negative are appropriate if they have been defined for the assay in clinical studies. By mentioning the assay and referencing the studies describing its properties (eg, sensitivity and specificity) and validating its usefulness in specific clinical settings, physicians and their patients will be reassured that the results they are getting are as meaningful as possible. Laboratories will be partially responsible for any harm done to patients resulting from inappropriate therapy based on invalid test results. Laboratories unable to validate their test should follow the methods of others in the literature who have. Tests that have not been validated should not be used at all.
